Trial Profile
A phase IIb trial of MVAHIV62 for the prevention of HIV infections in high-risk subjects
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2016
Price :
$35
*
At a glance
- Drugs GOVX-B11 (Primary) ; MVA-HIV62 (Primary)
- Indications HIV infections
- Focus Registrational; Therapeutic Use
- 16 Mar 2016 This trial is expected to begin in mid-2016, according to a GeoVax media release.
- 16 Mar 2016 Planned initiation date changed from 1 Jun 2015 to 1 Jul 2016, according to a GeoVax media release.
- 13 May 2015 Planned initiation date changed from 1 Jun 2014 to 1 Jun 2015.